Kytopen And Aldevron Announce Joint Marketing Agreement To Enhance Workflow Solutions For Cell Therapy Manufacturers

• Kytopen and Aldevron announce collaboration to expedite cell therapy manufacturing by combining their novel technologies.
• High transgene expression and improved safety profile of Aldveron's Nanoplasmid™ vector technology and the gentle gene-delivery of Kytopen's Flowfect Tx™ platform with unlimited scale, together offer enhanced CRISPR-mediated T-cell engineering resulting in high yields.
• A poster summarizing the data will be presented at ISCT, May 7-10, 2025, in New Orleans.

CAMBRIDGE, Mass. and FARGO, N.D., April 29, 2025 /PRNewswire/ -- Kytopen Corp., a leader in providing non-viral, continuous flow cellular engineering technologies and Aldevron, a leading global manufacturer serving organizations in the gene editing, mRNA vaccine and therapeutics, viral gene therapy, and modified gene therapy spaces; today announced, a joint marketing agreement aimed at enhancing the workflow solutions for cell therapy manufacturers. The collaboration will focus on the joint promotion of the synergies achieved by combining the Aldveron Nanoplasmid™ vector technology with Kytopen's Flowfect Tx™ GMP cellular engineering platform in CRISPR-mediated engineering of primary T Cells.